ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0236 • ACR Convergence 2025

    Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease

    Laura Bucci1, Sebastian Böltz1, Melanie Hagen1, Danae-Mona Nöthling1, Tobias Rothe2, Carlo Tur1, Andreas Wirsching1, Janina Auth3, jochen wacker1, Markus Eckstein4, Stefano Alivernini5, Aline Bozec1, Christina Bergmann1, Maria Antonietta D'Agostino6, Maria Gabriella Raimondo1, Georg Schett7 and Ricardo Grieshaber-Bouyer8, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 4Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 5Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 6Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
  • Abstract Number: 0291 • ACR Convergence 2025

    Acute onset inflammatory myositis: Clinical features and survival.

    Gollakota Nandita1, Madhuri Challa2, Phani Kumar D3, Meghna Gavali4 and Liza rajasekhar5, 1NIMS, Hyderabad, Hyderabad, Telangana, India, 2Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 3NIMS, Hyderabad, Telangana, India, 4nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, 5Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are characterized by subacute onset symmetric proximal muscle weakness, with occasional extra-muscular involvement, leading to significant morbidity and mortality. Acute…
  • Abstract Number: 0081 • ACR Convergence 2025

    Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis

    Jaeyeon Kim1, Sanaz Panahandeh2, Hieu Nguyen3, Kainat Mian4, Hadijat Makinde4, Kyoung Jae Won5, Arminja Kettenbach3, Harris R Perlman4, Costantino Pitzalis6 and Nunzio Bottini7, 1Cedars Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Northwestern University, Chicago, IL, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6QMUL, Bromley Kent, United Kingdom, 7Cedars Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: The discovery of circulating fibroblast-like synoviocyte (FLS), known as PRIME cells, in RA patients suggests that synovial FLS may enter the circulation through blood…
  • Abstract Number: 0317 • ACR Convergence 2025

    “No matter how great my doctor is, he hasn’t had a knee replacement, he doesn’t understand all that pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement

    Cara Murphy1, Sarah Young2, Vanessa Madrigal3, Noelia Hernandez4, Daniel Garcia5, Yuliana Dominguez Paez6, Monika Safford3, Iris Navarro-Millan7 and Mackenzie Brown8, 1HSS, New York, NY, 2Weill Cornell Medicine, Johnson City, NY, 3Weill Cornell Medicine, New York, 4Weill Cornell Medicine, New York, NY, 5Weill Cornell, Brooklyn, NY, 6Albert Einstein College of Medicine, The Bronx, NY, 7Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 8Weill Cornell Medicine, Brooklyn, NY

    Background/Purpose: Moving Well was a pre-habilitation peer coach intervention aimed at reducing levels of anxiety, depression, and pain among individuals undergoing total knee replacement (TKR)1.…
  • Abstract Number: 0290 • ACR Convergence 2025

    Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey

    Ezgi Sahin1, Omer Uludag2, yasemin yalcinkaya3, Bahar Artim Esen4, Ahmet Gul3 and Murat Inanc3, 1Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 4Istanbul University, Istanbul, Istanbul, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
  • Abstract Number: 0212 • ACR Convergence 2025

    Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases

    Noe Macias-Segura1, Rodolfo Martinez-Canales1, Andres M. Ortiz-Rios2, Braulio R. Avalos-Garcia2, Eva Abigaid Galindo-Calvillo2, Mario Cesar Salinas-Carmona1, Lorena Perez-Barbosa2, Dionicio A. Galarza-Delgado3 and Cassandra Michele Skinner-Taylor2, 1Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Therapeutic decisions during pregnancy in women with autoimmune rheumatic diseases (ARDs) such as SLE, APS, RA, and Sjögren’s syndrome require a personalized approach due…
  • Abstract Number: 0191 • ACR Convergence 2025

    Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK

    Aoibhinn Kelly1, Maddalena Rupnik2, Nasra Ahmed1, Mrinalini Dey3 and Elena Nikiphorou4, 1King's College Hospital NHS Foundation Trust, London, United Kingdom, 2Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 3Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 4King's College London, London, United Kingdom

    Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
  • Abstract Number: 0211 • ACR Convergence 2025

    Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration

    Alexandra Do1, Lisa Matsumoto1, Cherish Wilson2, Gary Tarasovsky3, gabriela Schmajuk4 and Jennifer Barton5, 1Oregon Health and Science University, Portland, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, 4University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 5VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
  • Abstract Number: 0097 • ACR Convergence 2025

    Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction

    Yosuke Ono1, Camilla R.L. Machado2, Eunice Choi1, Wei Wang1, David Boyle1 and Gary Firestein2, 1University of California, San Diego, San Diego, 2University of California, San Diego, San Diego, CA

    Background/Purpose: Fibroblast-like synoviocytes (FLS) play a central role in cartilage destruction and cytokine production in rheumatoid arthritis (RA). Neddylation, a post-translational modification involving NEDD8 conjugation,…
  • Abstract Number: 0323 • ACR Convergence 2025

    Automated Effusion-Synovitis Volume is Prognostic and Responsive to Knee Osteoarthritis Progression: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Kate Lapane2, Shao-Hsien Liu2, Jonggyu Baek2, Grace Lo3, Matthew Harkey4, Charles Eaton5, James Mackay6, Timothy McAlington7, Mohammad Chowdhury8, Zhen Cao9, Juan Shan10 and Ming Zhang11, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2UMass Chan Medical School, Worcester, MA, 3Baylor College of Medicine / MEDVAMC, Houston, TX, 4Michigan State University, East Lansing, MI, 5Brown University, Pawtucket, RI, 6University of Cambridge; Norwich Medical School, San Diego, CA, 7UMass Chan School of Medicine, Arlington, MA, 8Pace University, New York City, NY, 9Boston University, Boston, MA, 10Pace University, New York, NY, 11Boston University, Westford, MA

    Background/Purpose: Semi-quantitative and semi-automated quantitative measurements of effusion-synovitis (ES) are prognostic for knee OA progression. Changes in these metrics relate to changes in knee pain.…
  • Abstract Number: 0282 • ACR Convergence 2025

    Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes

    Shiri Keret1, Raisa Lomanto Silva2, Irada Choudhuri3, Eugenia Gkiaouraki3, Tanya Chandra3, Nantakarn Pongtarakulpanit3, Shreya Sriram3, Niladri Bhowmick3, Vaidehi Kothari3, Kaushik Sreerama Reddy3, Eaman Alhassan4, Anushka Aggarwal5, Maha Almackenzie6, Siamak Moghadam-Kia4, Dana Ascherman7, Chester V. Oddis7 and Rohit Aggarwal8, 1Bnai Zion Medical Center, Atlit, Israel, 2Massachusetts General Hospital, Boston, MA, 3University of Pittsburgh Medical Center, Pittsburgh, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Indraprastha Apollo Hospital, New Delhi, India, 6Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, 7University of Pittsburgh, Pittsburgh, PA, 8University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
  • Abstract Number: 0281 • ACR Convergence 2025

    Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies

    Anja Srpcic1, Manca Ogric1, Sasa Cucnik1, Sergej Pirkmajer2, Katja Lakota1 and Katja Perdan Pirkmajer1, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
  • Abstract Number: 0332 • ACR Convergence 2025

    Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis

    Mohamed Abdelsalam1, Maryam Lasheen2, Hadeer Hafez3, Bassant Elaraby Elsayed Badwy4, Omar Sameh Nabil El Sedafy1 and Mohamed Reda Awad5, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 2Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, 36th October University, 6 october, Al Jizah, Egypt, 4Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 5Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

    Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
  • Abstract Number: 0254 • ACR Convergence 2025

    Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis

    Justin Riley Lam1, Emmanuel Otabor2, Laith Alomari2, Michael Hamilton2, Maxim Barnett2, Shahrzad Abdollahi3 and Irene Tan4, 1Albert Einstein Medical Center, Philadelphia, PA, 2Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, 3Jefferson Einstein Hospital, Philadelphia, PA, 4Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA

    Background/Purpose: MAGIC syndrome, a rare overlap of relapsing polychondritis (RP) and Behçet’s disease manifestations, remains poorly characterized compared to isolated RP. Behçet’s-associated features such as…
  • Abstract Number: 0309 • ACR Convergence 2025

    A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative

    Julieann Patarini1, Timothy McAlington2, Jonggyu Baek1, Emily Kirillov3, Nhung Vo3, Michael Richard3, Ming Zhang4, Matthew Harkey5, Grace Lo6, Shao-Hsien Liu1, Kate Lapane1, Charles Eaton7, James Mackay8 and Jeffrey Driban9, 1UMass Chan Medical School, Worcester, MA, 2UMass Chan School of Medicine, Arlington, MA, 3Tufts Medical Center, Boston, MA, 4Boston University, Westford, MA, 5Michigan State University, East Lansing, MI, 6Baylor College of Medicine / MEDVAMC, Houston, TX, 7Brown University, Pawtucket, RI, 8University of Cambridge; Norwich Medical School, San Diego, CA, 9University of Massachusetts Chan Medical School, Marlborough, NH

    Background/Purpose: Cartilage defects are a hallmark of OA progression. We previously developed a composite MRI-based metric that combines cartilage damage from 6 anatomical regions throughout…
  • « Previous Page
  • 1
  • …
  • 75
  • 76
  • 77
  • 78
  • 79
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology